PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study.

doi:10.1016/j.jfma.2024.12.020

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study.

Journal of the Formosan Medical Association = Taiwan yi zhi - 1 Feb 2026

Yang Ching-Yao, Liao Wei-Yu, Ho Chao-Chi, Chen Kuan-Yu, Tsai Tzu-Hsiu, Hsu Chia-Lin, Su Kang-Yi, Chang Yih-Leong, Wu Chen-Tu, Hsu Chia-Chi, Liu Yi-Nan, Peng Guan-Ru, Kangartaputra Almanzo Aeterna, Yu Shu-Han, Liao Bin-Chi, Hsu Wei-Hsun, Lee Jih-Hsiang, Lin Chia-Chi, Shih Jin-Yuan, Chih-Hsin Yang James, Yu Chong-Jen

Abstract excerpt

BACKGROUND: PD-L1 is associated with poor efficacy of first- or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in untreated EGFR-mutant non-small-cell lung cancer (NSCLC). Whether PD-L1 is also predictive of osimertinib efficacy in pre-treated patients with an acquired EGFR T790 M mutation is unclear. PATIENTS AND METHODS: PD-L1 expression and tumor microenvironments...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to B7-H1 Antigen

Share to Indoles

Share to Kaplan-Meier Estimate

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Tumor Microenvironment

Source

Open in PubMed

Identifiers

PMID: 39694766
DOI: 10.1016/j.jfma.2024.12.020

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study.PMID 39694766Read ↗

Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer.Semantic proximity Read ↗

Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression.Semantic proximity Read ↗

Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib.Semantic proximity Read ↗

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients.Semantic proximity Read ↗

Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors.Semantic proximity Read ↗

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.Semantic proximity Read ↗

PD-L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non-small cell lung cancer with uncommon EGFR mutations treated with first-line second-generation EGFR-tyrosine kinase inhibitors.Semantic proximity Read ↗

PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.Semantic proximity Read ↗

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.Semantic proximity Read ↗

Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.Semantic proximity Read ↗

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.